Total Payments
$361,801
2024 Payments
$287,301
Companies
8
Transactions
65
Medicare Patients
9,631
Medicare Billing
$371,825
Payment Breakdown by Category
Research$264,150 (73.0%)
Consulting$77,725 (21.5%)
Other$19,680 (5.4%)
Food & Beverage$245.70 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $264,150 | 24 | 73.0% |
| Consulting Fee | $77,725 | 38 | 21.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,680 | 1 | 5.4% |
| Food and Beverage | $245.70 | 2 | 0.1% |
Payments by Type
Research
$264,150
24 transactions
General
$97,651
41 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Innovation | $260,600 | 16 | $0 (2024) |
| PFIZER INC. | $31,995 | 19 | $0 (2024) |
| Merck Sharp & Dohme LLC | $29,730 | 18 | $0 (2021) |
| Progenics Pharmaceuticals, Inc. | $19,680 | 1 | $0 (2021) |
| Ipsen Biopharmaceuticals, Inc | $16,600 | 2 | $0 (2022) |
| Ipsen Bioscience Inc. | $2,950 | 7 | $0 (2023) |
| ABBVIE INC. | $124.35 | 1 | $0 (2023) |
| Pharmacosmos Therapeutics Inc. | $121.35 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $287,301 | 29 | Ipsen Innovation ($260,600) |
| 2023 | $8,489 | 15 | PFIZER INC. ($5,415) |
| 2022 | $16,000 | 1 | Ipsen Biopharmaceuticals, Inc ($16,000) |
| 2021 | $25,825 | 6 | Progenics Pharmaceuticals, Inc. ($19,680) |
| 2020 | $7,850 | 4 | Merck Sharp & Dohme Corporation ($7,850) |
| 2019 | $16,335 | 10 | Merck Sharp & Dohme Corporation ($16,335) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $8,050.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 12/12/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $4,020.00 | General |
| Category: VACCINES | ||||||
| 12/12/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $2,460.00 | General |
| Category: VACCINES | ||||||
| 11/14/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $25,950.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 10/18/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| Category: VACCINES | ||||||
| 10/10/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $29,750.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 09/20/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $4,440.00 | General |
| Category: VACCINES | ||||||
| 09/12/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $21,650.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 08/22/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| Category: VACCINES | ||||||
| 08/14/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $43,900.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 07/18/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $2,130.00 | General |
| Category: VACCINES | ||||||
| 07/11/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $36,250.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 07/11/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $25,100.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 06/13/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: VACCINES | ||||||
| 06/13/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 06/06/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $9,300.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 05/23/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| Category: VACCINES | ||||||
| 05/02/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $13,700.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 05/02/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $121.35 | General |
| Category: HEMATOLOGY | ||||||
| 04/12/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| Category: VACCINES | ||||||
| 04/04/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $17,150.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 04/04/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $10,500.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 03/14/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| Category: VACCINES | ||||||
| 02/15/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: VACCINES | ||||||
| 02/08/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $10,550.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | Ipsen Innovation | $260,600 | 16 |
| A Phase 2, Two-part, Placebo-controlled, Parallel-group, Double-blind Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Participants 5 Years of Age and Older. | Ipsen Bioscience Inc. | $2,950 | 7 |
| A Phase 2, Two-part, Placebo-controlled, Parallel-group, Double-blind Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Participants 5 Years of Age and Older. | Ipsen Biopharmaceuticals, Inc | $600.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 2,341 | 2,442 | $330,507 | $74,702 |
| 2022 | 32 | 2,609 | 2,709 | $431,662 | $100,195 |
| 2021 | 29 | 2,170 | 2,241 | $405,965 | $98,060 |
| 2020 | 29 | 2,511 | 2,603 | $413,122 | $98,869 |
Total Patients
9,631
Total Services
9,995
Medicare Billing
$371,825
Procedure Codes
117
All Medicare Procedures & Services
117 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 476 | 512 | $71,680 | $16,101 | 22.5% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 183 | 185 | $55,685 | $12,786 | 23.0% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 157 | 161 | $46,207 | $10,772 | 23.3% |
| 72125 | Ct scan of upper spine without contrast | Facility | 2023 | 220 | 227 | $39,952 | $8,301 | 20.8% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2023 | 96 | 97 | $29,100 | $6,741 | 23.2% |
| 71045 | X-ray of chest, 1 view | Facility | 2023 | 360 | 393 | $11,790 | $2,777 | 23.6% |
| 71046 | X-ray of chest, 2 views | Facility | 2023 | 320 | 333 | $11,988 | $2,730 | 22.8% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2023 | 37 | 37 | $10,693 | $2,520 | 23.6% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2023 | 36 | 36 | $10,404 | $2,295 | 22.1% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 52 | 52 | $9,984 | $2,079 | 20.8% |
| 74174 | Ct scan of blood vessels of abdomen and pelvis with contrast | Facility | 2023 | 18 | 18 | $6,462 | $1,532 | 23.7% |
| 70551 | Mri scan of brain without contrast | Facility | 2023 | 22 | 22 | $5,390 | $1,262 | 23.4% |
| 70486 | Ct scan of face without contrast | Facility | 2023 | 33 | 33 | $4,653 | $1,054 | 22.7% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 17 | 17 | $3,485 | $701.55 | 20.1% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Facility | 2023 | 22 | 22 | $2,486 | $546.60 | 22.0% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Facility | 2023 | 28 | 28 | $2,072 | $492.80 | 23.8% |
| 73502 | X-ray of hip, 2-3 views | Facility | 2023 | 43 | 43 | $1,591 | $374.96 | 23.6% |
| 73030 | X-ray of shoulder, minimum of 2 views | Facility | 2023 | 38 | 38 | $1,178 | $280.82 | 23.8% |
| 74018 | X-ray of abdomen, 1 view | Facility | 2023 | 36 | 39 | $1,170 | $277.99 | 23.8% |
| 73562 | X-ray of knee, 3 views | Facility | 2023 | 29 | 29 | $930.00 | $216.60 | 23.3% |
| 72170 | X-ray of pelvis, 1-2 views | Facility | 2023 | 29 | 29 | $841.00 | $199.26 | 23.7% |
| 73130 | X-ray of hand, minimum of 3 views | Facility | 2023 | 22 | 22 | $667.00 | $157.78 | 23.7% |
| 72100 | X-ray of lower and sacral spine, 2-3 views | Facility | 2023 | 17 | 17 | $629.00 | $148.72 | 23.6% |
| 73610 | X-ray of ankle, minimum of 3 views | Facility | 2023 | 13 | 13 | $377.00 | $96.04 | 25.5% |
| 73630 | X-ray of foot, minimum of 3 views | Facility | 2023 | 14 | 14 | $392.00 | $92.66 | 23.6% |
About Dr. Craig Kolodziej, M.D
Dr. Craig Kolodziej, M.D is a Diagnostic Radiology healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023115672.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Craig Kolodziej, M.D has received a total of $361,801 in payments from pharmaceutical and medical device companies, with $287,301 received in 2024. These payments were reported across 65 transactions from 8 companies. The most common payment nature is "" ($264,150).
As a Medicare-enrolled provider, Kolodziej has provided services to 9,631 Medicare beneficiaries, totaling 9,995 services with total Medicare billing of $371,825. Data is available for 4 years (2020–2023), covering 117 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Boca Raton, FL
- Active Since 09/17/2006
- Last Updated 01/13/2010
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1023115672
Products in Payments
- PREVNAR 20 (Biological) $31,995
- MK-4280 (Biological) $24,185
- VENCLEXTA (Drug) $124.35
- MONOFERRIC (Drug) $121.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Boca Raton
Dr. Kathy Schilling, Md, MD
Diagnostic Radiology — Payments: $112,799
Diagnostic Radiology $112,799
Dr. Peter Okolo, Md, MD
Diagnostic Radiology — Payments: $21,507
Diagnostic Radiology $21,507
Dr. George Khoriaty, Md, MD
Diagnostic Radiology — Payments: $12,030
Diagnostic Radiology $12,030
Dr. Steven Needell, M.d, M.D
Diagnostic Radiology — Payments: $10,852
Diagnostic Radiology $10,852
Dr. Douglas Deorchis, M.d, M.D
Diagnostic Radiology — Payments: $4,662
Diagnostic Radiology $4,662
Dr. Jonathan Wiener, M.d, M.D
Diagnostic Radiology — Payments: $2,081
Diagnostic Radiology $2,081